Alkermes Plc
Change company Symbol lookup
Select an option...
ALKS Alkermes Plc
CPTNW Cepton Equity Warrant Exp 10th Feb 2027 *W EXP 02/10/2027
APPF Appfolio Inc
FMN Federated Hermes Premier Municipal Inc
USCTU TKB Critical Technologies 1
SIEGY Siemens AG
FDBC Fidelity D&D Bancorp Inc
$BUKCHET Bloomberg Coffee Subindex Euro
BMY Bristol-Myers Squibb Co
MLGO MicroAlgo Inc
Go

Health Care : Biotechnology | Small Cap Growth
Based in Ireland
Company profile

Alkermes Public Limited Company is an integrated biopharmaceutical company. It is engaged in researching, developing and commercializing pharmaceutical products that are designed to address unmet medical needs of patients in the fields of neuroscience and oncology. Its portfolio of commercial products focused on alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of product candidates in development for neurodegenerative disorders and cancer. Its products include ARISTADA, ARISTADA INITIO, LYBALVI and VIVITROL. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder. VIVITROL is a non-narcotic, injectable medication for the treatment of alcohol dependence and for the prevention of relapse to opioid dependence, following opioid detoxification.

Closing Price
$27.10
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Below Average)
Volume:
978,528

10-day average volume:
1,145,105
978,528

INVESTIGATION NOTICE: Kaskela Law LLC Announces Stockholder Investigation into Fairness of Poshmark, Inc. (POSH) Buyout Offer and Encourages Investors to Contact the Firm

4:12 pm ET November 12, 2022 (Globe Newswire) Print
INVESTIGATION NOTICE: Kaskela Law LLC Announces Stockholder Investigation into Fairness of Poshmark, Inc. (POSH) Buyout Offer and Encourages Investors to Contact the FirmGlobeNewswireNovember 12, 2022

PHILADELPHIA, Nov. 12, 2022 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Poshmark, Inc. (NASDAQ: POSH) ("Poshmark") on behalf of the company's investors.

On October 3, 2022, Poshmark announced that it had agreed to be acquired by Naver Corp. ("Naver"). According to the announcement, Poshmark's stockholders are expected to be cashed out of their investment position at a price of $17.90 per share in cash, a price that is over 10% lower than POSH's 52-week high value.



The investigation seeks to determine whether Poshmark's officers and/or directors failed to maximize the buyout price for Poshmark's stockholders, or otherwise breached their fiduciary duties in agreeing to sell the company to Naver.

Poshmark shareholders are encouraged to contact Kaskela Law LLC (Adrienne Bell, Esq.) at (484) 229 - 0750, or by email (abell@kaskelalaw.com) or online at https://kaskelalaw.com/cases/poshmark-inc/, to receive additional information about this investigation and their legal rights and options.

Kaskela Law LLC exclusively represents investors in securities fraud, corporate governance, and merger & acquisition litigation. For additional information about Kaskela Law LLC please visit www.kaskelalaw.com. This notice may constitute attorney advertising in certain jurisdictions.

CONTACT:

D. Seamus Kaskela, Esq.

Adrienne Bell, Esq.

KASKELA LAW LLC

18 Campus Blvd., Suite 100

Newtown Square, PA 19073

(484) 229 - 0750

(888) 715 - 1740

www.kaskelalaw.com



Primary Logo

comtex tracking

COMTEX_418732515/2010/2022-11-12T16:12:55

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.